Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

NCT00139620 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.

NCT NCT00139620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00139620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Lead sponsor
OSI Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
August 22, 2005
Completion date
June 25, 2007
Enrollment
39 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors